Geron Corporation (NASDAQ:GERN) said the US Food and Drug Administration ordered a halt to trials of a cancer drug over concerns about potential liver damage. Geron Corporation (NASDAQ:GERN) stock performance was -61.59% in last session and finished the day at $1.69. Traded volume was 46,444,384 million shares in the last session and the average volume of the stock remained 4.64 million shares. The beta of … Continue reading Biotech Top Losers: Geron Corporation (NASDAQ:GERN), Synta Pharmaceuticals (NASDAQ:SNTA), Northwest Biotherapeutics (NASDAQ:NWBO), AEterna Zentaris (NASDAQ:AEZS)